The DOI matches its Crossref record; 60 of the 60 references it cites were found in a registry or an index.
Preclinical Evaluation of Efficacy and Safety of an Improved Lentiviral Vector for the Treatment of β-Thalassemia and Sickle Cell Disease
Open accessAbstract
A previously published clinical trial demonstrated the benefit of autologous CD34(+) cells transduced with a selfinactivating lentiviral vector (HPV569) containing an engineered β-globin gene (β(A-T87Q)-globin) in a subject with β thalassemia major. This vector has been modified to increase transduction efficacy without compromising safety. In vitro analyses indicated that the changes resulted in both increased vector titers (3 to 4 fold) and increased transduction efficacy (2 to 3 fold). An in vivo study in which 58 β-thalassemic mice were transplanted with vector- or mock-transduced syngenic bone marrow cells indicated sustained therapeutic efficacy. Secondary transplantations involving 108 recipients were performed to evaluate long-term safety. The six month study showed no hematological or biochemical toxicity. Integration site (IS) profile revealed an oligo/polyclonal hematopoietic reconstitution in the primary transplants and reduced clonality in secondary transplants. Tumor cells were detected in the secondary transplant mice in all treatment groups (including the control group), without statistical differences in the tumor incidence. Immunohistochemistry and quantitative PCR demonstrated that tumor cells were not derived from transduced donor cells. This comprehensive efficacy and safety data provided the basis for initiating two clinical trials with this second generation vector (BB305) in Europe and in the USA in patients with β-thalassemia major and sickle cell disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
![Fig. (1) In vitro evaluation of LentiGlobin lentiviral vectors. A) Diagram of the LentiGlobin HPV569 and BB305 lentiviral vectors. The 3′ β-globin enhancer, the 372 base pairs (bp) IVS2 deletion in intron 2 (triangle), the βA-T87Q mutation (ACA [Thr] to CAG [Gln]) and DNase I hypersensitive sites (HS) 2, HS3, and HS4 of the human β-globin locus control region (LCR) are indicated. Safety modifications including the 400 bp deletion in the U3 of the right HIV LTR, the rabbit β-globin polyA signal and the 2 × 250 bp cHS4 chromatin insulators are indicated. βp, human β-globin promoter; cPPT/flap, central polypurine tract; HIV LTR, human immunodeficiency type-1 virus long-terminal repeat; ppt, polypurine tract; RRE, Rev-responsive element; Ψ+, packaging signal. B) Functional (transducing unit/mL) and physical (ng p24/mL) titers of lentiviral vectors produced in HEK293T cells, before (harvest) and after purification/concentration (final). C) Y axis: Vector copies = Average vector copy number per cell in transduced human CD34+ cells. D) Y axis: Vector copies = Average vector copy numbers per cell in transduced progenitor cells, using either short-term cultures to determine colony forming cells (CFCs) or long-term cultures to determine long-term culture initiating cells (LTC-ICs). MOI was 50. E) HPLC profile of globin chains from pooled erythroid colonies obtained from HPV569 (top) and BB305 (bottom) lentiviral vector-transduced CD34+ cells. F) Y axis: βA-T87Q globin chains as a percentage of all non-α globin chains as detected by HPLC.](https://figures.cochat.ai/paper-figures/f5c1b2dee2414ff2b920bd1df5832003/preclinical-evaluation-of-efficacy-and-safety-of-an-improved-lentiviral-vector-figure-1.jpg)



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Limited changes in the LentiGlobin vector (HPV569 vs. BB305) did not significantly alter the expression of β A-T87Q -globin per integrated vector copy, but they contributed (along with changes in vector manufacturing) to an increase in vector titers by a factor of approximately 4. 14,24,37”
From Gene Therapy in Patients with Transfusion-Dependent β-Thalassemia (2018) · cites this paper as [24]
The cited source says what the claim attributes to it.
In the citing paper
“Limited changes in the LentiGlobin vector (HPV569 vs. BB305) did not significantly alter the expression of β A-T87Q -globin per integrated vector copy, but they contributed (along with changes in vector manufacturing) to an increase in vector titers by a factor of approximately 4. 14,24,37”
From Gene Therapy in Patients with Transfusion-Dependent β-Thalassemia (2018) · cites this paper as [24]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
LMO2 -Associated Clonal T Cell Proliferation in Two Patients after Gene Therapy for SCID-X1
Hacein-Bey-Abina, S., Von Kalle, C., Schmidt, M., McCormack, M. P., Wulffraat, N., Leboulch, P., Lim, A., Osborne, C. S., Pawliuk, R., Morillon, E., et al. (2003) · Science · doi:10.1126/science.1088547 · Cited by 3,587
Self-citationHIV-1 Integration in the Human Genome Favors Active Genes and Local Hotspots
Schröder, A. R. W., Shinn, P., Chen, H., Berry, C., Ecker, J. R., & Bushman, F. (2002) · Cell · doi:10.1016/s0092-8674(02)00864-4 · Cited by 1,832
Hematopoietic Stem Cell Gene Therapy with a Lentiviral Vector in X-Linked Adrenoleukodystrophy
Cartier, N., Hacein-Bey-Abina, S., Bartholomae, C. C., Veres, G., Schmidt, M., Kutschera, I., Vidaud, M., Abel, U., Dal-Cortivo, L., Caccavelli, L., et al. (2009) · Science · doi:10.1126/science.1171242 · Cited by 1,508 · cited 1×
“Human genetic diseases have been treated successfully by gene therapy with lentiviral vectors, as shown for the first time in the treatment of subjects with childhood cerebral adrenoleukodystrophy (CCALD) [1, 2] and (cid:1) -thalassemia major [3, 4].”
BackgroundSelf-citationGalanello, R., & Origa, R. (2010) · Orphanet Journal of Rare Diseases · doi:10.1186/1750-1172-5-11 · Cited by 1,466
Transfusion independence and HMGA2 activation after gene therapy of human β-thalassaemia
Cavazzana-Calvo, M., Payen, E., Negre, O., Wang, G., Hehir, K., Fusil, F., Down, J., Denaro, M., Brady, T., Westerman, K., et al. (2010) · Nature · doi:10.1038/nature09328 · Cited by 1,276 · cited 9×
“We previously reported that a patient with -thalassemia major ( / ) became transfusion independent after autologous transplantation with CD34 cells transduced with the LentiGlobin HPV569 lentiviral vector [3].”
BackgroundInfluentialSelf-citationLentiviral Hematopoietic Stem Cell Gene Therapy Benefits Metachromatic Leukodystrophy
Biffi, A., Montini, E., Lorioli, L., Cesani, M., Fumagalli, F., Plati, T., Baldoli, C., Martino, S., Calabria, A., Canale, S., et al. (2013) · Science · doi:10.1126/science.1233158 · Cited by 1,180
Self-citationThe protein CTCF is required for the enhancer blocking activity of vertebrate insulators
Bell, A. C., West, A. G., & Felsenfeld, G. (1999) · Cell · doi:10.1016/s0092-8674(00)81967-4 · Cited by 1,101
Ott, M. G., Schmidt, M., Schwarzwaelder, K., Stein, S., Siler, U., Koehl, U., Glimm, H., Kühlcke, K., Schilz, A., Kunkel, H., et al. (2006) · Nature Medicine · doi:10.1038/nm1393 · Cited by 1,051
Self-citationLentiviral Hematopoietic Stem Cell Gene Therapy in Patients with Wiskott-Aldrich Syndrome
Aiuti, A., Biasco, L., Scaramuzza, S., Ferrua, F., Cicalese, M. P., Baricordi, C., Dionisio, F., Calabria, A., Giannelli, S., Castiello, M. C., et al. (2013) · Science · doi:10.1126/science.1233151 · Cited by 1,025
Self-citationProduction, concentration and titration of pseudotyped HIV-1-based lentiviral vectors
Kutner, R. H., Zhang, X.-Y., & Reiser, J. (2009) · Nature Protocols · doi:10.1038/nprot.2009.22 · Cited by 668
Self-citation
Research works printed but not linked: 2
- [32]Morawietz G. Ruehl-Fehlert C. Kittel B. Revised guides for organ sampling and trimming in rats and mice--Part 3. A joint publication of the RITA and NACAD groups. Exp. Toxicol. Pathol. 2004 55 433 449 15384249
- [40]Negre O. Bartholoma C. Kutner R. Abstract 674 of the American Society of Gene & Cell Therapy (ASGGT) 16th Annual Meeting. May 15-18, 2013. Salt Lake City, Utah, USA. Mol. Ther. 2013 21 Suppl. 1 s257 23728215
Cited by
Gene therapy in a patient with sickle cell disease
Ribeil, J.-A., Hacein-Bey-Abina, S., Payen, E., Magnani, A., Semeraro, M., Magrin, E., Caccavelli, L., Neven, B., Bourget, P., El Nemer, W., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1609677 · Cited by 696
Self-citationGene Therapy in Patients with Transfusion-Dependent β-Thalassemia
Thompson, A. A., Walters, M. C., Kwiatkowski, J., Rasko, J. E. J., Ribeil, J.-A., Hongeng, S., Magrin, E., Schiller, G. J., Payen, E., Semeraro, M., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1705342 · Cited by 684
Self-citationBetibeglogene Autotemcel Gene Therapy for Non–β 0 /β 0 Genotype β-Thalassemia
Locatelli, F., Thompson, A. A., Kwiatkowski, J. L., Porter, J. B., Thrasher, A. J., Hongeng, S., Sauer, M. G., Thuret, I., Lal, A., Algeri, M., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2113206 · Cited by 283
Self-citationMolecular basis of α-thalassemia
Farashi, S., & Harteveld, C. L. (2018) · Blood Cells, Molecules, and Diseases · doi:10.1016/j.bcmd.2017.09.004 · Cited by 227
Acute Myeloid Leukemia Case after Gene Therapy for Sickle Cell Disease
Goyal, S., Tisdale, J., Schmidt, M., Kanter, J., Jaroscak, J., Whitney, D., Bitter, H., Gregory, P. D., Parsons, G., Foos, M., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2109167 · Cited by 211
Self-citation
Metadata
- Authors
- Negre, O., Bartholomae, C., Beuzard, Y., Cavazzana, M., Christiansen, L., Courne, C., Deichmann, A., Denaro, M., Dreuzy, E., Finer, M., Fronza, R., Gillet-Legrand, B., Joubert, C., Kutner, R., Leboulch, P., Maouche, L., Paulard, A., Pierciey, F., Rothe, M., Ryu, B., Schmidt, M., Kalle, C., Payen, E., & Veres, G.
- Affiliations
- German Cancer Research Center (DE)
- Université Paris-Saclay (FR)
- Bluebird Bio (France) (FR)
- Commissariat à l'Énergie Atomique et aux Énergies Alternatives (FR)
- Harvard University (US)
- Medizinische Hochschule Hannover (DE)
- Corresponding author
- Payen, Emmanuel
- Veres, Gabor
- ORCID
- Venue
- Current Gene Therapy
- Publisher
- Bentham Science Publishers Ltd.
- Published
- 2014-12-26
- Volume
- 15
- Issue
- 1
- Pages
- 64-81
- ISSN
- 1566-5232 (ISSN-L)
- PMC
- PMC4440358
- OpenAlex
- W2116613468
- Cited by
- 126
- References
- 59
- Citations by year
- 2026: 6 · 2025: 10 · 2024: 8 · 2023: 9 · 2022: 9 · 2021: 17 · 2020: 9 · 2019: 12 · 2018: 14 · 2017: 12 · 2016: 15 · 2015: 5
- FWCI
- 7.01
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- cc-by-nc
- Locations
- Current Gene Therapy (publishedVersion)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Digital Access to Scholarship at Harvard (DASH) (Harvard University) (submittedVersion, cc-by)
- Funders
- bluebird bio
- Agence Nationale de la Recherche
- Institut National de la Santé et de la Recherche Médicale
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Health Sciences › Medicine › Genetics (clinical) › Hemoglobinopathies and Related Disorders
- Health Sciences › Medicine › Hematology › Hematopoietic Stem Cell Transplantation
- Keywords
- beta-thalassemia major, sickle cell disease, lentiviral vectors, self-inactivating vectors, beta-globin gene, vector titer, bone marrow transplantation, serial transplantation, hematopoietic recovery, tumor incidence, gene therapy safety
- MeSH terms
- Anemia, Sickle Cell, Animals, Disease Models, Animal, DNA Damage, Female, Genetic Vectors, Male, Mice, Inbred C57BL, Genetic Therapy, Gene Expression, Lentivirus, beta-Thalassemia, Gene Transfer Techniques, Hematopoietic Stem Cell Transplantation, Antigens, CD34, Computational Biology, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Preclinical Evaluation of Efficacy and Safety of an Improved Lentiviral Vector for the Treatment of β-Thalassemia and Sickle Cell Disease. https://app.cochat.ai/papers/10.2174/1566523214666141127095336
- The paper
- Negre, O., Bartholomae, C., Beuzard, Y., Cavazzana, M., Christiansen, L., Courne, C., Deichmann, A., Denaro, M., Dreuzy, E., Finer, M., Fronza, R., Gillet-Legrand, B., Joubert, C., Kutner, R., Leboulch, P., Maouche, L., Paulard, A., Pierciey, F., Rothe, M., . . . Veres, G. (2014). Preclinical Evaluation of Efficacy and Safety of an Improved Lentiviral Vector for the Treatment of β-Thalassemia and Sickle Cell Disease. Current Gene Therapy. https://doi.org/10.2174/1566523214666141127095336
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.